Reducing the Incidence of Colorectal Cancer
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The prevalence of colorectal cancer could be reduced by 95% with proper screening in every patient at recommended age intervals. That’s according to Dr. Steven Stryker, professor of clinical surgical oncology at Northwestern University’s Feinberg School of Medicine. Yet colorectal cancer remains the second most common cancer in America. Dr. Stryker joins host Dr. Lauren Streicher to explain how physicians can encourage patient compliance with current screening modalities. What circumstances favor virtual screening? Are there other common procedures that can facilitate the diagnosis of colorectal cancer?
Overview
The prevalence of colorectal cancer could be reduced by 95% with proper screening in every patient at recommended age intervals. That’s according to Dr. Steven Stryker, professor of clinical surgical oncology at Northwestern University’s Feinberg School of Medicine. Yet colorectal cancer remains the second most common cancer in America. Dr. Stryker joins host Dr. Lauren Streicher to explain how physicians can encourage patient compliance with current screening modalities. What circumstances favor virtual screening? Are there other common procedures that can facilitate the diagnosis of colorectal cancer?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Level Up Your Skills: Tailoring Management of HF
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Second-line Chemotherapy Options in Metastatic PDAC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?